MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
6.74
+0.79
+13.28%
After Hours: 6.66 -0.08 -1.13% 19:44 02/06 EST
OPEN
6.09
PREV CLOSE
5.95
HIGH
6.87
LOW
6.06
VOLUME
867.20K
TURNOVER
--
52 WEEK HIGH
7.73
52 WEEK LOW
1.340
MARKET CAP
351.51M
P/E (TTM)
-8.7058
1D
5D
1M
3M
1Y
5Y
1D
Immix Biopharma Inc. unveils new presentation on relapsed/refractory AL amyloidosis treatment challenges
Reuters · 3d ago
Weekly Report: what happened at IMMX last week (0126-0130)?
Weekly Report · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
Reuters · 01/28 18:37
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
Reuters · 01/28 15:48
BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy
Reuters · 01/28 14:01
Immix Biopharma Granted Breakthrough Therapy Designation From FDA To NXC-201 To Treat Relapsed/Refractory AL Amyloidosis
Benzinga · 01/28 13:48
FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis
Reuters · 01/28 13:45
IMMIX BIOPHARMA INC: FINAL DATA EXPECTED THIS YEAR FOLLOWED BY PLANNED BLA SUBMISSION
Reuters · 01/28 13:45
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.